BioCryst Pharmaceuticals Inc. (BCRX)

2.68
0.09 3.47
NASDAQ : Health Technology
Prev Close 2.59
Open 2.60
Day Low/High 2.55 / 2.69
52 Wk Low/High 2.54 / 9.95
Volume 1.44M
Avg Volume 2.36M
Exchange NASDAQ
Shares Outstanding 110.44M
Market Cap 284.93M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
January 2015 Options Now Available For BioCryst Pharmaceuticals (BCRX)

January 2015 Options Now Available For BioCryst Pharmaceuticals (BCRX)

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading today, for the January 2015 expiration.

BioCryst Initiates OPuS-1: A Phase 2a Clinical Trial Of BCX4161 In Patients With Hereditary Angioedema

BioCryst Initiates OPuS-1: A Phase 2a Clinical Trial Of BCX4161 In Patients With Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has dosed the first subject in OPuS-1 ( Oral Prophylaxi S-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in...

BioCryst Provides Corporate Update And Reports Third Quarter 2013 Financial Results

BioCryst Provides Corporate Update And Reports Third Quarter 2013 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter ended September 30, 2013.

6 Charts Explain An Ugly October for Biotech Stocks

6 Charts Explain An Ugly October for Biotech Stocks

For only the second time in 2013, the S&P 500 beat biotech stocks in October.

BioCryst To Announce Third Quarter 2013 Financial Results November 5

BioCryst To Announce Third Quarter 2013 Financial Results November 5

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third quarter 2013 financial results will be released on Tuesday, November 5, 2013.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

3 Biotech Stocks Under $10 Making Big Moves

3 Biotech Stocks Under $10 Making Big Moves

Keep these under-$10 biotech stocks on your radar.

BioCryst Awarded Contract By The National Institute Of Allergy And Infectious Diseases (NIAID) To Develop BCX4430 For The Treatment Of Marburg Virus Disease

BioCryst Awarded Contract By The National Institute Of Allergy And Infectious Diseases (NIAID) To Develop BCX4430 For The Treatment Of Marburg Virus Disease

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has contracted with BioCryst for the development of BCX4430 as a treatment...

BioCryst To Present At Morgan Stanley Global Healthcare Conference

BioCryst To Present At Morgan Stanley Global Healthcare Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the ...

Biotech Stock Mailbag: MannKind, Osiris, BioCryst, Vical, Amarin

Biotech Stock Mailbag: MannKind, Osiris, BioCryst, Vical, Amarin

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

'Mad Money' Lightning Round: Sell, Sell, Sell IBM

'Mad Money' Lightning Round: Sell, Sell, Sell IBM

Cramer is sticking with Krispy Kreme and is no friend to MannKind.

Cramer's 'Mad Money' Recap: From a Headwind to a Tailwind

Cramer's 'Mad Money' Recap: From a Headwind to a Tailwind

There has been a remarkable turn in the markets and it's coming from an area where we least expect it, Cramer said.

BioCryst Provides Corporate Update And Reports Second Quarter 2013 Financial Results

BioCryst Provides Corporate Update And Reports Second Quarter 2013 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2013.

BioCryst Announces Full Exercise Of Over Allotment Option

BioCryst Announces Full Exercise Of Over Allotment Option

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the underwriters of its recent public offering of its common stock have exercised in full their option to purchase an additional 600,000 shares.

Top Insider Trades: BCRX, SFM, PMCS, ACCL

Top Insider Trades: BCRX, SFM, PMCS, ACCL

The top 10 open-market insider purchases and sales filed at the SEC Friday.

BioCryst To Announce Second Quarter 2013 Financial Results August 8

BioCryst To Announce Second Quarter 2013 Financial Results August 8

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its second quarter 2013 financial results will be released on Thursday, August 8, 2013.

BioCryst Pharmaceuticals Prices Public Offering Of Common Stock

BioCryst Pharmaceuticals Prices Public Offering Of Common Stock

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price to the public of $4.

BioCryst Announces Proposed Public Offering Of Common Stock

BioCryst Announces Proposed Public Offering Of Common Stock

BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that it is offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective shelf registration statement in an...

Fred Cohen Appointed To BioCryst’s Board Of Directors

Fred Cohen Appointed To BioCryst’s Board Of Directors

BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that Fred E.

BioCryst Successfully Completes Its Phase 1 Clinical Trial Of BCX4161 For The Treatment Of Hereditary Angioedema

BioCryst Successfully Completes Its Phase 1 Clinical Trial Of BCX4161 For The Treatment Of Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its...

BioCryst To File Peramivir NDA Supported By BARDA/HHS Funding

BioCryst To File Peramivir NDA Supported By BARDA/HHS Funding

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the Biomedical Advanced Research and Development Authority (BARDA/HHS) has released funding under the current $234.

July Options Now Available For BioCryst Pharmaceuticals (BCRX)

July Options Now Available For BioCryst Pharmaceuticals (BCRX)

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading today, for the July expiration.

5 Stocks Under $10 Set to Surge

5 Stocks Under $10 Set to Surge

These under-$10 stocks look poised to trade higher from current levels.

5 Health Care Stocks Under $10 to Watch

5 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Stocks Gain as Alcoa Beats on Profit

Stocks Gain as Alcoa Beats on Profit

Major U.S. stock markets turn higher as Alcoa reported earnings that exceeded expectations.

BioCryst Won't Profit From Bird Flu Outbreak in China

BioCryst Won't Profit From Bird Flu Outbreak in China

BioCryst doesn't own rights to the version of peramivir approved in China.

Stock Futures Rise as GE to Buy Lufkin for $3.3 Billion

Stock Futures Rise as GE to Buy Lufkin for $3.3 Billion

Stock futures are rising Monday as investors anticipate the start of earnings season with Alcoa's report.

BioCryst Announces Initiation Of A Phase 1 Clinical Trial Of BCX4161 For The Treatment Of Hereditary Angioedema

BioCryst Announces Initiation Of A Phase 1 Clinical Trial Of BCX4161 For The Treatment Of Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX4161 in healthy...

BioCryst Reports Fourth Quarter And Full Year 2012 Financial Results

BioCryst Reports Fourth Quarter And Full Year 2012 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2012.

BioCryst To Announce Fourth Quarter & 2012 Financial Results On February 19, 2013

BioCryst To Announce Fourth Quarter & 2012 Financial Results On February 19, 2013

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its fourth quarter and full year 2012 financial results will be released on Tuesday, February 19, 2013.

TheStreet Quant Rating: D- (Sell)